RNP Therapeutics

We are developing combination therapy targeting tumor microenvironment (TME) by modulating non-coding RNA in combination with PD-1/PD-L1 checkpoint therapy

  • Stage Product In Development
  • Industry Biotechnology
  • Location Boston, MA, USA
  • Currency USD
  • Founded June 2019
  • Employees 2
  • Incorporation Type Not Incorporated
  • Website rnptx.com

Company Summary

RNP Therapeutics is engaging non-coding RNA (ncRNA) to target the components of tumor microenvironment (TME). TME is a battle ground between tumor and host immune system. To date, RNP Therapeutics has developed a platform for targeting the component of TME through modulating non-coding RNA, such as microRNA, 3' UTR and lncRNA. We have identified promising drug candidate to improve tumor response to PD1/PD-L1 checkpoint therapy

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free